# Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors

> **NCT03610971** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 24 (actual)

## Conditions studied

- Chronic Phase Chronic Myeloid Leukemia
- Chronic Myeloid Leukemia, Chronic Phase

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** BCR-ABL Tyrosine Kinase Inhibitor (TKI)

## Key facts

- **NCT ID:** NCT03610971
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-11-19
- **Primary completion:** 2025-09-25
- **Final completion:** 2026-10
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2026-04-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03610971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03610971, "Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT03610971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*